Immunologic Effects of Sirolimus in Patients with Vascular Anomalies

Akifumi Nozawa, Michio Ozeki, Shiho Yasue, Saori Endo, Norio Kawamoto, Hidenori Ohnishi, Shigehisa Fumino, Taizo Furukawa, Tatsuro Tajiri, Takanobu Maekawa, Akihiro Fujino, Ryota Sozaki, Toshiyuki Fukao

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)


Emerging data have suggested that sirolimus may be a treatment option for complicated vascular anomalies (VAs). The present study aimed to investigate the immunologic effects of sirolimus treatment for 6 months in patients with VAs. Blood samples obtained from the patients enrolled in 2 multicenter studies to investigate the efficacy of sirolimus for VAs before and after sirolimus treatment for 6 months were used. Data for total white blood cell count, absolute lymphocyte count, serum immunoglobulins (Igs) levels (IgG, IgA, IgM), lymphocyte proliferation assays with mitogens including phytohemagglutinin and concanavalin A, and flow cytometric analysis of lymphocyte subsets were evaluated. A total of 18 patients with VAs receiving sirolimus treatment were included in the study. Comparisons of white blood cell, absolute lymphocyte count, IgG, IgA, IgM, and reaction rates of phytohemagglutinin and concanavalin A revealed no significant differences before and after treatment. No significant differences were observed in the absolute counts of lymphocyte subtypes before and after treatment, except for regulatory T-cell counts, which were significantly decreased after treatment. Severe infections were not observed during sirolimus treatment. The immunologic parameters assessed in the present study were hardly affected by sirolimus treatment for 6 months in patients with VAs.

ジャーナルJournal of Pediatric Hematology/Oncology
出版ステータス出版済み - 7 1 2020

All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康
  • 血液学
  • 腫瘍学


「Immunologic Effects of Sirolimus in Patients with Vascular Anomalies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。